Market Place
Sourcing Support
Novo Nordisk`s Hemlibra rival hits goals in phase 3, teeing up blockbuster showdown with Roche
15 May 2024 //
PRESS RELEASE
New data reinforce benefit of early preventative treatment with Roche™s Hemlibra
09 Dec 2023 //
GLOBENEWSWIRE
EC approves label expansion of Hemlibra to include people with haemophilia A
01 Feb 2023 //
GLOBENEWSWIRE
Sanofi offers up more Hemlibra rival data as FDA decision looms
27 Jan 2023 //
FIERCE BIOTECH
CHMP recommends expansion of EU label for Hemlibra
16 Dec 2022 //
GLOBENEWSWIRE
Data from phase III study presented at ASH show Hemlibra achieved bleed control
11 Dec 2022 //
GLOBENEWSWIRE
Interim Data From PIII Study Presented Show Hemlibra Achieved Bleed Control
11 Dec 2022 //
BUSINESSWIRE
Sanofi nabs priority review for hemophilia A as pharma awaits FDA decision
31 Aug 2022 //
ENDPTS
Japan-Specific Approval For Hemlibra In Acquired Hemophilia A
20 Jul 2022 //
SCRIP
New data from PIII HAVEN 6 study show favourable profile of Roche`s Hemlibra
11 Jul 2022 //
GLOBENEWSWIRE
Genentech`s Hemlibra emicizumab-kxwh Receives Supplemental Approval in U.S.
06 Jun 2022 //
FDA
Genentech`s Biologic Hemlibra (Emicizumab) Receives Approval in the U.S.
16 Dec 2021 //
FDA
Roche’s Hemlibra shows bleed control in Phase III haemophilia trial
14 Dec 2021 //
CLINICALTRIALSARENA
Interim Data From Phase III HAVEN 6 Study of Hemlibra in Hemophilia A
13 Dec 2021 //
BUSINESSWIRE
Chugai Files for Additional Indication of Hemlibra for Acquired Hemophilia A
11 Nov 2021 //
FIRSTWORDPHARMA
Chugai Pharma’s Hemlibra gets Japanese ODD status for acquired hemophilia A
04 Oct 2021 //
PHARMABIZ
Genentech`s Biologics Emicizumab Receives Approval in the US
02 Sep 2021 //
FDA
Genentech’s Hemlibra Reinforce Safety Profile in Hemophilia A
19 Jul 2021 //
BUSINESSWIRE
Roche to present new data at the ISTH 2021 Congress
02 Jul 2021 //
GLOBENEWSWIRE
ICER Publishes Evidence Report on Therapies for Hemophilia A
16 Oct 2020 //
ICER
Spark Therapeutics nabs CMO from new owner Roche
11 Aug 2020 //
FIERCE BIOTECH
New Interim Results Ph IIIb Study Reinforce the Long-Term Safety of Chugai’s
13 Jul 2020 //
BUSINESSWIRE
New data reinforces safety profile of Roche’s Hemlibra
13 Jul 2020 //
PMLIVE
Clinical management support: Known interference between Hemlibra®
18 Apr 2020 //
GC
Novo Nordisk hits pause on rival to Hemlibra for haemophilia
18 Mar 2020 //
PMLIVE
Ocrevus, Hemlibra offset Roche`s biosim loss
30 Jan 2020 //
FIERCE PHARMA
Taiwan FDA approves Chugai’s Hemlibra for Hemophilia A
31 Oct 2019 //
BIOSPECTRUMASIA
Chugai’s Hemlibra Approved for Hemophilia A Without Inhibitors in Taiwan
30 Oct 2019 //
BUSINESSWIRE
Roche — surprise — delays $4.3B Spark buyout again as regulators hover
30 Oct 2019 //
ENDPTS
Novo taps bluebird bio for gene-editing tech
10 Oct 2019 //
FIERCE BIOTECH
Roche sets new deadline for Spark acquisition as divestiture speculation brews
30 Sep 2019 //
ENDPTS
Is the FTC about to force Roche to divest a key hemophilia program
26 Sep 2019 //
ENDPTS
Roche and Spark Continue to See Delays for Pending Deal
07 Sep 2019 //
BIOSPACE
Roche`s Tecentriq, on an EU hot streak, bags 2 new lung cancer approvals
07 Sep 2019 //
FIERCEPHARMA
Roche`s Hemlibra widens its patient pool in England
22 Aug 2019 //
FIERCE PHARMA
NHS to reimburse Hemlibra
21 Aug 2019 //
PHARMA TIMES
Roche touts torrent of Hemlibra data amid hemophilia gene therapy deal delays
10 Jul 2019 //
FIERCE PHARMA
Roche touts phase 2 Gazyva data in lupus patients
12 Jun 2019 //
FIERCE PHARMA
Roche snags first-in-class FDA nod for lymphoma drug Polivy
11 Jun 2019 //
FIERCE PHARMA
Roche’s Acquisition of Spark Hits Another Regulatory Snag in the U.S. and U.K.
11 Jun 2019 //
BIOSPACE
Roche`s New Cancer, MS Drugs Pay Off With a Forecast Boost
18 Apr 2019 //
BLOOMBERGQUINT
Hemlibra off to a flyer as Roche raises 2019 forecasts
17 Apr 2019 //
PMLIVE
Roche`s drugs, new and old, team up for major sales
17 Apr 2019 //
FIERCE PHARMA
Roche & Chugai`s Hemlibra scoops up EU approval-severe haemophilia A
14 Mar 2019 //
PHARMAFILE
Storm clouds gather over pharma companies as price hikes ease
05 Feb 2019 //
STAT NEWS
Chugai’s Hemlibra® Gains Positive CHMP Opinion in Severe Hemophilia A
04 Feb 2019 //
BUSINESSWIRE
Committee for medicinal products for human use (CHMP)
28 Jan 2019 //
EMA
ICER lays out plans to scrutinize pharma`s costliest price hikes
22 Jan 2019 //
FIERCE PHARMA
Emmetuxumab injection for rare disease treatment was approved for marketing
11 Dec 2018 //
CHINA NMPA
Gilead locks in Daniel O’Day as CEO, tapping the Roche vet to rejuvenate growth
11 Dec 2018 //
ENDPTS
Roche says Hemlibra effective in pivotal study
04 Dec 2018 //
REUTERS
Soliris (eculizumab) : Chugai Pharmaceutical vs. Alexion Pharmaceuticals
26 Nov 2018 //
PATENT LITIGATION
7 drugs that raised eyebrows in Q3
16 Nov 2018 //
BIOPHARMA DIVE
Novartis says its top drug prospect is worth $4M-$5M for a once-and-done use
05 Nov 2018 //
ENDPTS
Shire`s Takhzyro gets off to hot start, boosting immunology sales
03 Nov 2018 //
FIERCE PHARMA
Genentech to Present New Data from Its Industry-Leading Hematology Portfolio
01 Nov 2018 //
BUSINESSWIRE
All revved up and ready to roll, Roche going to multibillion-$ hemophilia mkt
05 Oct 2018 //
ENDPTS
Roche’s Hemlibra breaks into hemophilia market with blockbuster approval
05 Oct 2018 //
FIERCE PHARMA
U.S. FDA expands approval of Roche hemophilia drug
05 Oct 2018 //
REUTERS
